Evidence map›Paper›PMID 38864137›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2024

[Tofacitinib inhibits the transformation of lung fibroblasts into myofibroblasts through JAK/STAT3 pathway].

Shan He, Xin Chen, Qi Cheng, Lingjiang Zhu, Peiyu Zhang, Shuting Tong, Jing Xue, Yan DU

Abstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shan HeDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Xin ChenDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Qi ChengDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Lingjiang ZhuDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Peiyu ZhangDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Shuting TongDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Jing XueDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Yan DUDepartment of Rheumatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect of tofacitinib, a pan-Janus kinase (JAK) inhibitor, on transforming growth factor-beta 1 (TGF-β1)-induced fibroblast to myofibroblast transition (FMT) and to explore its mechanism. To provide a theoretical basis for the clinical treatment of connective tissue disease-related interstitial lung disease (CTD-ILD).

methods(1) Human fetal lung fibroblast 1 (HFL-1) were cultured

results(1) Tofacitinib inhibited the viability and migration ability of HFL-1 cells after TGF-β1 induction. (2) The expression of

conclusionTofacitinib can inhibit the transformation of HFL-1 cells into myofibroblasts induced by TGF-β1, and the mechanism may be through inhibiting the classic Smad2/3 pathway as well as the phosphorylation of STAT3 induced by TGF-β1, thereby protecting the disease progression of pulmonary fibrosis.

Indexed as

FibroblastsMyofibroblastsPiperidinesPyrimidinesSignal TransductionSTAT3 Transcription FactorActinsCell MovementCells, CulturedCell SurvivalCollagen Type IFibronectinsHumansInterleukin-6Janus KinasesLungACTA2 protein, humanActinsCollagen Type IFibronectinsInterleukin-6Janus KinasesPiperidinesPyrimidinesPyrrolesSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSTAT3 protein, humanSTAT3 Transcription FactortofacitinibTransforming Growth Factor beta1FibroblastsMyofibroblastsPulmonary fibrosisSTAT3 transcription factorTofacitinib

Identifiers

PMID38864137
PMCPMC11167539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.